My practice is involved with a large number of drug studies on eye drugs for various retinal conditions. When these studies are initiated a lot of thought goes into trying to design the study as likely to work as possible. Recently one of the drug companies had a failed study. They analyzed the study and decided that the way it was set up allowed the study to fail. So feeling confident that their product would ultimately pass muster they set up another study done slightly differently which they hope will succeed. This INR stuff is a lot like that. Concoct weird statistics (adding bleeding+stroke) showing they are "superior" in one group and getting the FDA to OK this device. Also I think there is a trend for the FDA to OK things that possibly in the past would not be OKed. For example one of the drugs for Alzheimers was authorized even though it did not show direct clinical efficacy for Alzheimers. It only showed a marker being altered. Somewhat like the defense industry in the US there is a revolving door between government and industry in other departments like the FDA. So there may be conflicts of interest in making these decisions.
Wise man. I agree with everything you said above.
I used to work in the pharma industry. For about 5 years I was a programmer involved with creating the reports that were used for FDA submissions, mostly phase II clinical trials.
Adverse effects was always our biggest shall we say "challenge". Those reports would be reviewed & "massaged" (IE: altered) up the wazoo to increase the chances of FDA approval at the direction of the MDs overseeing the studies working for the pharma company. If the adverse events were too serious or common the data would be looked at with a microscope to find ways to exclude "outliers" resulting in a more favorable report, or simply scrap the study and implement a new study with more targeted "patient screening" likely to get better results.
Then add to this that the FDA is motivated largely by $$ as is the whole industry of course. The greater the perceived profits the more likely whatever it is will get approval by the FDA. And there are the ties of FDA employees who came from big pharma with relationships with their old companies even if not out in the open salary drawing situations. The whole system is corrupt and the FDA is largely toothless or at least chooses to be.
Yeah I'm generalizing but if you think the FDA's #1 focus is to protect patients I have some prime real estate avialable for sale real cheap down around New Orleans or Northern California you might want to invest in.
[Edit: By the word "you" above I don't mean vitdoc, I mean anyone reading my post. And - as I say "don't get me started" - what the FDA does regarding approving generics is downright pathetic IMO based on my own personal experience]